Home › Subarachnoid Hemorrhage › NCT07294118

Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage

Endovascular Infusion of Lidocaine and Steroids in the Middle Meningeal Artery for Pain Management in Spontaneous Subarachnoid Hemorrhage Patients

Who can join

Ages 18 to 100 · All sexes

Inclusion Criteria:

* Age ≥18 years.
* Diagnosed with aneurysmal SAH, Hunt and Hess Grades 1-2.
* Consent to study procedures and follow-up evaluations.

Exclusion Criteria:

* Known allergies to lidocaine or steroids.
* Arteriovenous malformations.
* Dural Arteriovenous Fistulas.
* Other significant intracranial pathologies.
* Hemodynamic instability preventing safe intervention.
* Previous MMA interventions.
* Previous craniotomies or need for craniotomy.
* Need for external ventricular drain.

About the study

The goal of this clinical trial is to learn if an infusion of lidocaine, with or without steroids, into the middle meningeal artery (MMA) helps relieve severe headaches in patients with spontaneous subarachnoid hemorrhage (SAH). It will also study the safety of this treatment.

What is being tested

• Lidocaine (drug)
• Lidocaine and Dexamethasone (drug)

Sponsor: The University of Texas Medical Branch, Galveston · Participants: 15 · Started: Jan 2, 2026

Contact the study team

• Matias Costa · Phone: 409-772-1011

Official record on ClinicalTrials.gov — NCT07294118

Locations in the U.S.

Conditions

• Subarachnoid Hemorrhage
• Headache
• Opioid Overdose

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.